Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. Laroni A, Giacomazzi CG, Grimaldi L, Gallo P, Sormani M, Bertolotto A, McDermott JL, Gandoglia I, Martini I, Vitello G, et al. J Neuroimmune Pharmacol. 2012 May 16. Epub 2012 May 16. PMID: 22585413. Abstract CommentRecommendBookmarkWatch